While the share of ESI enrollees with a GLP-1 drug claim has been increasing, still only a relatively modest number of people have a claim Since 2012, the share of non-elderly adults with ESI that have a GLP-1 drug claim has grown more than eightfold (717.7% increase)
21, article 172, 2022, Lincoff, A
What should I know about combining GLP-1 medications with insulin or sulfonylureas
Both brand-name and compounded options may be available depending on provider evaluation and current legal requirements
Poor physical performance identifies severe sarcopenia
Concomitant therapy with metformin, incretins, and SGLT2 inhibitors should be continued with regimens containing bolus insulin to support glycemic management with less risk of weight gain and hypoglycemia [75,76,81-102]